TNBC is widely recognized as the most difficult breast cancer to treat because it is very aggressive and does not respond to ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal ...

Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...

Prostatic-specific antigen (PSA) is commonly used as a screening tool for prostate cancer but presents limited sensitivity and specificity. Therefore, research efforts are focused on searching for ...

This article was review by Thomas Cooper, MD from Baylor College of Medicine. Stay up to date on the latest science with Brush Up Summaries. Despite its significance, alternative splicing’s global ...

Splicing is a process necessary for the correct synthesis of proteins and an essential step in gene expression. An impaired minor splicing may lead to aberrant pre-mRNA transcripts and exon skipping, ...